VEGFR
All Product Categories
-
VEGFR Inhibitors
(337)
View all products
-
VEGFR Agonists
(5)
View all products
-
VEGFR Antagonists
(4)
View all products
-
VEGFR Activators
(7)
View all products
-
VEGFR Modulators
(6)
View all products
-
VEGFR Chemical
(1)
View all products
-
VEGFR Inducer
(1)
View all products
-
VEGFR Ligands
(3)
View all products
-
VEGFR Related Products (403)
Related Products (403)
-
Bevasiranib sodium
0 ImagesCat. No.: HY-153484ACAS No.: 849758-52-7Bevasiranib sodium is a siRNA that targets and silences VEGF-A. Bevasiranib sodium activates the RNA-induced silencing complex to degrade VEGF-A mRNA, mediates TLR3-related inhibition of choroidal neovascularization, and triggers RNA interference-mediated gene silencing through endogenous eukaryotic RNAi mechanisms. After intravitreal injection, Bevasiranib sodium distributes to various ocular tissues and resists degradation by intraocular nucleases, reducing choroidal neovascularization area and alleviating vascular leakage. Bevasiranib sodium can be used in research related to macular degeneration.
-
Peptide HRH acetate
0 ImagesCat. No.: HY-P11775APeptide HRH acetate is a polypeptide that specifically binds to VEGF receptors. Peptide HRH acetate inhibits VEGF-stimulated endothelial cell proliferation. Peptide HRH acetate inhibits angiogenesis and suppresses corneal neovascularization. Peptide HRH acetate can be used in anti-angiogenesis related studies.
-
hVEGF-IN-3
0 ImageshVEGF-IN-3 (compound 9) is a potent hVEGF inhibitor. hVEGF-IN-3 inhibits HT-29, MCF-7, and HEK-293 cells proliferation with IC50s of 61, 142, and 114 μM.
-
Taurocholic acid-d8 sodium
0 ImagesSynonyms: Sodium taurocholate-d8 (Standard); N-Choloyltaurine-d8 sodiumTaurocholic acid-d8 (sodium) is deuterium labeled Taurocholic acid (sodium). Taurocholic acid sodium (Sodium taurocholate) has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Taurocholic acid sodium has immunoregulation effect.
-
Nintedanib-13C,d3
0 ImagesCat. No.: HY-50904S1Synonyms: BIBF 1120-13C,d3Nintedanib-13C,d3 is the 13C- and deuterium labeled Nintedanib. Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.
-
Cabozantinib-d4
0 ImagesSynonyms: XL184-d4; BMS-907351-d4
-
Flt2-11
0 ImagesFlt2-11 is a anti-angiogenic peptide, and specifically binds NRP-1. Flt2-11 inhibits NRP-1/sVEGFR-1 interaction.
-
Hydroxytanshinone IIA
0 ImagesHydroxytanshinone IIA is a hydrolytic metabolite of Tanshinone IIA (HY-N0135). Tanshinone IIA inhibits angiogenesis by targeting the protein kinase domain of VEGF/VEGFR2. Hydroxytanshinone IIA exhibits antioxidant and anti-inflammatory activities. Hydroxytanshinone IIA can be used in studies of angina pectoris and myocardial infarction.
-
hVEGF-IN-1
0 ImageshVEGF-IN-1, a quinazoline derivative, could specifically bind to the G-rich sequence in the internal ribosome entry site A (IRES-A) and destabilize the G-quadruplex structure. hVEGF-IN-1 binds to the IRES-A (WT) with a Kd of 0.928 μM in SPR experiments. hVEGF-IN-1 could hinder tumor cells migration and repress tumor growth by decreasing VEGF-A protein expression.
-
IMS2186
0 ImagesIMS2186 is an anti-choroidal neovascularization (CNV) agent that inhibits angiogenesis upstream of VEGF. IMS2186 can arrest cancer cell cycle in G2/M phase, thus exerting anti-proliferation and anti-angiogenesis effects. IMS2186 has no intraocular toxicity and reduces the amount of eye leakage and diseased cells.
-
Pazopanib-13C,d3 hydrochloride
0 ImagesCat. No.: HY-12009SCAS No.: 1261398-44-0Synonyms: GW786034-13C,d3 hydrochloride
-
Arginyl-Glutamine TFA
0 ImagesCat. No.: HY-P4253APurity: 99.22%Synonyms: H-Arg-Gln-OH TFAArginyl-Glutamine TFA is a dipeptide that can decrease VEGF levels and inhibit retinal neovascularization in a mouse model of oxygen-induced retinopathy.
-
Tanshinone IIA (Standard)
0 ImagesTanshinone IIA (Standard) is the analytical standard of Tanshinone IIA. This product is intended for research and analytical applications. Tanshinone IIA (Tan IIA) is one of the main compositions in the root of Salvia miltiorrhiza Bunge. Tanshinone IIA may suppress angiogenesis by targeting the protein kinase domains of VEGF/VEGFR2.
-
VEGFR-2-IN-37
0 ImagesVEGFR-2-IN-37 (compound 12) is an inhibitor of VEGFR-2. The inhibition rate at 200 μM was approximately 56.9 μM. VEGFR-2-IN-37 is a potential inhibitor of human umbilical vein endothelial cell (HUVEC) proliferation.
-
Regorafenib-d3
0 ImagesSynonyms: BAY 73-4506-d3Regorafenib-d3 (BAY 73-4506-d3) is a deuterium labeled Regorafenib (HY-10331). Regorafenib is a multi-targeted receptor tyrosine kinase inhibitor.
-
Nintedanib-d3
0 ImagesSynonyms: BIBF 1120-d3Nintedanib-d3 is the deuterium labeled Nintedanib. Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.
-
VEGFR-2-IN-6
0 ImagesVEGFR-2-IN-6 (example 64) is a VEGFR2 inhibitor (angiogenesis modulator), which is extracted from patent WO 02/059110.
-
Taurocholic acid-13C2,15N sodium
0 ImagesCat. No.: HY-N0545SCAS No.: 2483830-59-5Synonyms: Sodium taurocholate-13C2,15N; N-Choloyltaurine-13C2,15N sodiumTaurocholic acid-13C2,15N (sodium) is the 13C- and 15N- labeled Taurocholic acid (sodium).
